Effects of epinephrine and cyclic AMP phosphodiesterase inhibitors on the glycogen synthetic pathway and glucose content in skeletal muscle.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D000242:Cyclic AMP / Q000378:metabolism; D003964:Diaphragm / Q000378:metabolism; D004837:Epinephrine / Q000494:pharmacology*; D005947:Glucose / Q000378:metabolism*; D005958:Glucosephosphates / Q000378:metabolism; D006003:Glycogen / Q000096:biosynthesis* / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D008757:Methylglucosides / Q000378:metabolism; D009132:Muscles / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors; D051381:Rats
D005958:Glucosephosphates; D008757:Methylglucosides; D010726:Phosphodiesterase Inhibitors; D006003:Glycogen; D000242:Cyclic AMP; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D005947:Glucose; D004837:Epinephrine